# A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

> **NCT01704963** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Mature B-cell Neoplasms

## Interventions

- **DRUG:** PCI-32765

## Key facts

- **NCT ID:** NCT01704963
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-12
- **Primary completion:** 2015-11-20
- **Final completion:** 2017-02-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01704963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01704963, "A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01704963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*